Biomarkers for Alzheimer's Disease
Global Alzheimer's Disease Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Alzheimer's Disease Antibodies Market Opportunity: > USD 5 Billion
- Alzheimer's Disease Clinical Trials Insight: > 200 Drugs In Trials
- Alzheimer's Disease Biomarkers Sourced During Clinical Trials
- Alzheimer's Disease Insight By Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report: https://www.kuickresearch.com/ccformF.php?t=1648033875
Alzheimer is a disease which is characterized by the degeneration of nerve cells in several areas of brain. The disease is characterized by the loss of cognitive functions including memory, language, thinking, and behavior. The common symptoms of Alzheimer include depression, memory impairment, loss of inhibitions, and problem with thinking and reasoning. Several factors including diabetes, obesity, high blood pressure, and unhealthy dietary patterns increases the risk of developing the disease.
Currently, there is no cure available for the disease as the entire drugs approved for the disease works on reducing the symptoms rather than targeting the underlying mechanism of the disease. However, the advancement in the field of science and technology has enabled the researchers for the identification of novel targets which have critical role in the progression of the disease. The efforts done by the researchers have ultimately led to the development of several disease modifying agents which are currently present under clinical trials and have shown promising results. Recently, in June 2021, the FDA granted accelerated approval for the first disease modifying therapy, AduhelmT (Aducanumab), developed by Biogen, for the treatment of Alzheimer's disease. The approval of this amyloid beta-directed antibody has sparked a ray of hope for other players which are seeking approval for similar therapies.
The lack of techniques for the diagnosis of disease is expected to limit the growth of Alzheimer drugs market. At present, there is no definitive blood test, brain scan, or physical exam to diagnose Alzheimer disease, and so many conditions can produce symptoms like dementia which make the identification of disease more complicated. Lack of proper and quick diagnosis for Alzheimer disease hampers the growth of market as it leads to reduce number of cancer cases and thereby reduces the consumption of drugs. However, research is being done to develop novel techniques for the early diagnosis of the disease. Recently, PrecivityAD test has entered the market which identifies whether a patient is likely to have amyloid plaques in the brain. Currently, the test is being used in major National Institute of Health funded drug study at 75 centers. The commercialization of these tests in coming years will boost the market growth.
The rising incidence of the disease associated with the need of targeted therapies in its management is boosting the growth of market. Biopharmaceutical industries globally are relentlessly working over to meet the therapeutic demands of novel Alzheimer drugs. The pipeline of Alzheimer drugs is highly concentrated and contains majority of disease modifying agents providing a ray of hope to better future treatments in Alzheimer. The global Alzheimer drug market is moderately competitive and consists of several major players. With technological advancements and product innovation, small pharmaceutical giants are expanding their market presence by introducing new technologies with better results. Companies including Roche, Novartis, Pfizer, Mylan, and Teva Pharmaceuticals hold significant share in market.
As per our report findings, the global Alzheimer drug market is expected to reach US$ 10 Billion by 2026, which is mainly due to growing prevalence of the disease. US holds the largest share in the global market which is mainly due to rising geriatric population, increasing number of research studies, and presence of majority of key players in the region. Moreover, growing awareness about the disease among the population as well as government initiatives to promote the research and development activities in this area will drive the growth of market. Currently, Europe has the highest old population accounting for 25% of the population, whereas Asia Pacific regions including India, China, and Japan also have considerable geriatric population. Therefore, these regions hold the potential opportunities for the target market during the forecast period.